CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
819.46MUSDvs all stocks (USD)
Revenue (TTM)
418.24MUSDvs all stocks (USD)
Profit Margin
-1.77%Beta
1.06xvs all stocks
52-Week Change
176.52%vs all stocks
Market Capitalization
819.46MUSDvs all stocks (USD)
Enterprise Value
1.21BUSDvs all stocks (USD)
Forward P/E
12.35xPrice to Sales (TTM)
1.96xEnterprise to Revenue
2.88xEnterprise to EBITDA
15.89xGross Margin
56.84%Profit Margin
-1.77%Operating Margin
-8.22%Return on Assets (TTM)
12.04%Revenue (TTM)
418.24MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.89USDUpdated Jul 18, 2026Quarterly Revenue Growth
23.20%Gross Profit (TTM)
241.70MUSDvs all stocks (USD)
EBITDA (TTM)
63.87MUSDvs all stocks (USD)
Net Income (TTM)
-7.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
23.25%Operating Cash Flow (TTM)
-18.19MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-49.71MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Payout Ratio
0.00%Revenue
403.13MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
129.22MUSDFY2025 · Dec 31, 2025Gross Profit
273.91MUSDFY2025 · Dec 31, 2025Operating Income
60.27MUSDvs all stocks (USD)
Pre-tax Income
-20.84MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.84MUSDFY2025 · Dec 31, 2025Net Income
-22.68MUSDFY2025 · Dec 31, 2025EBIT
63.76MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.87MUSDFY2025 · Dec 31, 2025Research & Development
47.85MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
165.79MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
84.60MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1100USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1100USDFY2025 · Dec 31, 2025Basic Shares Outstanding
207.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
207.87MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-22.68MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-13.52MUSDFY2025 · Dec 31, 2025Free Cash Flow
-13.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
167.85MUSDFY2025 · Dec 31, 2025Income Tax Paid
612.00KUSDFY2025 · Dec 31, 2025Interest Paid
16.27MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-22.68MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
105.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
14.26MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-60.05MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
20.92MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
24.07MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00USDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-54.91MUSDFY2025 · Dec 31, 2025Common Dividends Paid
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-7.26MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
25.84MUSDFY2025 · Dec 31, 2025Shares Outstanding
257.40MSharesUpdated Jul 18, 2026Float Shares
234.89MSharesUpdated Jul 18, 2026Shares Short
17.40MSharesUpdated Jul 18, 2026Short Ratio
1.58daysvs all stocks
Short % of Shares Outstanding
6.87%vs all stocks
% Held by Insiders
0.91%vs all stocks
% Held by Institutions
71.54%vs all stocks
Total Cash (MRQ)
156.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6070USDUpdated Jul 18, 2026Total Debt (MRQ)
543.81MUSDvs all stocks (USD)
Current Ratio (MRQ)
1.53xBook Value per Share (MRQ)
-1.20USDUpdated Jul 18, 2026Total Assets
465.89MUSDvs all stocks (USD)
Total Current Assets
462.57MUSDFY2025 · Dec 31, 2025Total Liabilities
767.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
467.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
300.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
167.85MUSDFY2025 · Dec 31, 2025Accounts Receivable
140.19MUSDFY2025 · Dec 31, 2025Inventory
105.12MUSDFY2025 · Dec 31, 2025Accounts Payable
65.07MUSDFY2025 · Dec 31, 2025Short-term Debt
2.10MUSDFY2025 · Dec 31, 2025Deferred Revenue
34.48MUSDFY2025 · Dec 31, 2025Other Current Liabilities
87.60MUSDFY2025 · Dec 31, 2025Long-term Debt
250.13MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
216.91MUSDFY2025 · Dec 31, 2025Common Stock (Book)
245.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.62BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-301.96MUSDvs all stocks (USD)
Treasury Stock
55.00MUSDFY2025 · Dec 31, 202552-Week Low
1.13USDUpdated Jul 18, 202652-Week High
4.18USDUpdated Jul 18, 202652-Week Change
176.52%vs all stocks
Beta
1.06xvs all stocks
50-Day MA
3.15USDUpdated Jul 18, 2026200-Day MA
3.09USDUpdated Jul 18, 2026Avg 10-Day Volume
19.84MSharesUpdated Jul 18, 2026Avg 30-Day Volume
14.15MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.1100USDUpdated Jul 18, 2026Other Income / Expense
3.49MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.23Receivables vs revenue divergence: 9.54
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: -0.02
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow